BIOGEN for BIOGEN
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committee |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Trade (domestic/foreign) TRD
Support for strong IP protections for biologics and pharmaceuticals, consistent with US law, to be included in the Trans-Pacific Partnership (TPP) trade agreement.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committee |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Taxation/Internal Revenue Code TAX
Support domestic and international corporate tax policies which protect and incentivize US-based research and manufacturing jobs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committee |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Health Issues HCR
Support for reauthorization of the Prescription Drug User Fee Act (PDUFA V) to: 1) Improve the transparency and predictability of the FDA drug review process. 2) Allow for modifications to the REMS program to improve communication and accuracy of information to providers and patients. 3) Expand existing FDA authority to allow for accelerated approval for products that address severe and life threatening diseases.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ADAM GLUCK | Staff, Senate HELP Committe |
| KATHLEEN TREGONING | Staff, House Ways and Means Committee |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.